News - Janssen Pharmaceutica

Filter

Current filters:

Janssen Pharmaceutica

Popular Filters

Janssen reveals new data on Xeplion in various stages of schizophrenia

Janssen reveals new data on Xeplion in various stages of schizophrenia

30-11-2013

US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen Pharmaceutica…

Invega SustennaJanssen PharmaceuticaJohnson & JohnsonNeurologicalPharmaceuticalResearchXeplion

European health R&D investments stagnate for the first time in history

European health R&D investments stagnate for the first time in history

08-10-2013

A report published yesterday shows that European research and development investments in health have…

EuropeFinancialJanssen PharmaceuticaPharmaceutical

Warning over Janssen's Nizoral tablets

30-07-2013

The US Food and Drug Administration is taking action over anti-fungal Nizoral (ketoconazole) oral tablets…

Antibiotics and Infectious diseasesJanssen PharmaceuticaNizoralNorth AmericaPharmaceuticalRegulation

Janssen submits NDA for "breakthrough" leukemia and lymphoma drug ibrutinib

11-07-2013

Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), has submitted…

ibrutinibJanssen PharmaceuticaJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini

15-05-2012

In a two part transaction, USA-based Furiex Pharmaceuticals (Nasdaq: FURX) has entered into an agreement…

ALZA CorpFuriex PharmaceuticalsJanssen PharmaceuticaJohnson & JohnsonLicensingMen's HealthMenariniPharmaceuticalPriligy

Forest Labs buys Bystolic rights from Janssen for $357 million

03-04-2012

Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

Affymax and Janssen Biotech enter $13 million peginesatide patent settlement

11-11-2011

US biotech firm Affymax (Nasdaq: AFFY) says it has reached a global settlement agreement with Janssen…

AffymaxBiotechnologyJanssen PharmaceuticaJohnson & JohnsonOncologyPatentspeginesatidePharmaceuticalTakeda Pharmaceuticals

US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients

07-11-2011

In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C

21-09-2011

The European Commission has approved Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Incivo (telaprevir),…

Anti-viralsEuropeIncivekIncivoJanssen PharmaceuticaJohnson & JohnsonPharmaceuticalRegulationtelaprivirVertex

Janssen Biotech gets FDA delay for new Simponi indication

12-09-2011

The US Food and Drug Administration has issued a Complete Response letter (CRL) to Janssen Biotech, a…

Anti-Arthritics/RheumaticsBiotechnologyJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

US FDA advisory panel backs approval of Bayer/J&J’s Xarelto for stroke prevention

09-09-2011

There must have been a palpable sigh of relief last night across Leverkusen, the headquarters of Germany’s…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Johnson & Johnson’s Nucynta OKed by US FDA for moderate to severe chronic pain

30-08-2011

US health care giant Johnson & Johnson (NYSE: JN) group company Janssen Pharmaceuticals says that the…

GrunenthalJanssen PharmaceuticaJohnson & JohnsonNeurologicalNorth AmericaNucyntaPharmaceuticalRegulationtapentadol

UK’s NICE recommends Celgene’s Thalidomide and Janssen’s Velcade for multiple myeloma

27-07-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published a final…

CelgeneEuropeJanssen PharmaceuticaJohnson & JohnsonOncologyPharmaceuticalPricingRegulationThalidomideVelcade

FDA advisory panel backs Janssen’s Remicade for pediatric use in ulcerative colitis

25-07-2011

A US Food and Drug Administration advisory committee has recommended the approval of health care major…

Gastro-intestinalsJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationRemicade

Jubilant in neuroscience drug discovery alliance with Janssen

29-06-2011

In a second piece of good news on deals with a drug major for the Indian group in a matter of days, Jubilant…

Janssen PharmaceuticaJohnson & JohnsonJubilantLicensingOphthalmicsPharmaceuticalResearch

Johnson & Johnson invests $30 million in deal with Russia’s Skolkovo

23-06-2011

US health care giant Johnson & Johnson (NYSE: JNJ), together with its pharmaceutical division Janssen…

Anti-viralsEuropeFinancialJanssen PharmaceuticaJohnson & JohnsonOncologyPharmaceuticalResearch

Back to top